Profile data is unavailable for this security.
About the company
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).
- Revenue in USD (TTM)0.00
- Net income in USD-102.04m
- Incorporated2010
- Employees57.00
- LocationMind Medicine (MindMed) IncOne World Trade Center, Suite 8500NEW YORK 10007United StatesUSA
- Phone+1 (212) 220-6633
- Fax+1 (888) 848-3972
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Terns Pharmaceuticals Inc | 0.00 | -95.90m | 629.62m | 66.00 | -- | 2.40 | -- | -- | -1.31 | -1.31 | 0.00 | 3.11 | 0.00 | -- | -- | 0.00 | -36.84 | -41.34 | -38.72 | -45.70 | -- | -- | -- | -31,010.30 | -- | -- | 0.00 | -- | -- | -- | -49.49 | -- | -26.60 | -- |
Third Harmonic Bio Inc | 0.00 | -39.20m | 632.90m | 51.00 | -- | 2.34 | -- | -- | -0.9694 | -0.9694 | 0.00 | 6.59 | 0.00 | -- | -- | 0.00 | -13.36 | -- | -13.66 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 12.32 | -- | -- | -- |
Sana Biotechnology Inc | 0.00 | -244.90m | 642.93m | 328.00 | -- | 1.89 | -- | -- | -1.15 | -1.15 | 0.00 | 1.53 | 0.00 | -- | -- | 0.00 | -36.94 | -38.99 | -42.11 | -42.70 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.11 | -- | 112.71 | -- |
Alumis Inc | 0.00 | -189.03m | 644.14m | 128.00 | -- | -- | -- | -- | -3.65 | -3.65 | 0.00 | 3.87 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -142.57 | 0.00 | -- | -- | -- | -38.47 | -- | -- | -- |
Allogene Therapeutics Inc | 43.00k | -283.43m | 646.15m | 232.00 | -- | 1.40 | -- | 15,026.85 | -1.53 | -1.53 | 0.0002 | 2.21 | 0.00007 | -- | -- | 185.34 | -43.56 | -28.46 | -46.04 | -30.21 | -- | -- | -659,137.20 | -1,123.44 | -- | -- | 0.00 | -- | -39.10 | -- | 3.86 | -- | -14.06 | -- |
Mind Medicine (MindMed) Inc | 0.00 | -102.04m | 657.79m | 57.00 | -- | 3.20 | -- | -- | -2.26 | -2.26 | 0.00 | 2.80 | 0.00 | -- | -- | 0.00 | -49.75 | -- | -61.24 | -- | -- | -- | -- | -- | -- | -- | 0.1072 | -- | -- | -- | -68.55 | -- | -- | -- |
Y-mAbs Therapeutics Inc | 86.55m | -24.61m | 662.75m | 100.00 | -- | 6.95 | -- | 7.66 | -0.5618 | -0.5618 | 1.98 | 2.14 | 0.6262 | 1.42 | 4.19 | 865,460.00 | -17.81 | -44.23 | -23.58 | -50.45 | 88.74 | -- | -28.44 | -181.13 | 2.72 | -- | 0.00 | -- | 29.96 | -- | 77.58 | -- | -- | -- |
Astria Therapeutics Inc | 0.00 | -93.24m | 668.64m | 59.00 | -- | 2.59 | -- | -- | -2.30 | -2.30 | 0.00 | 6.32 | 0.00 | -- | -- | 0.00 | -32.43 | -64.48 | -33.78 | -68.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.62 | -- | -- | -- |
Savara Inc | 0.00 | -75.29m | 669.92m | 37.00 | -- | 5.53 | -- | -- | -0.4317 | -0.4317 | 0.00 | 0.7361 | 0.00 | -- | -- | 0.00 | -58.02 | -36.86 | -62.14 | -39.54 | -- | -- | -- | -102,587.50 | -- | -- | 0.2066 | -- | -- | -- | -43.38 | -- | 15.91 | -- |
Tectonic Therapeutic Inc | 0.00 | -58.25m | 678.82m | 13.00 | -- | 4.08 | -- | -- | -18.52 | -18.52 | 0.00 | 11.29 | 0.00 | -- | -- | 0.00 | -35.55 | -45.22 | -40.16 | -49.14 | -- | -- | -- | -- | -- | -128.75 | 0.0066 | -- | -- | -- | 111.48 | -- | -66.27 | -- |
AnaptysBio Inc | 57.17m | -165.66m | 681.60m | 117.00 | -- | 8.08 | -- | 11.92 | -6.07 | -6.07 | 2.09 | 2.77 | 0.1166 | -- | 7.39 | 488,649.60 | -33.78 | -18.08 | -36.91 | -18.96 | -- | -- | -289.75 | -269.21 | -- | -- | 0.00 | -- | 66.78 | 27.97 | -27.11 | -- | -5.36 | -- |
Korro Bio Inc | 0.00 | -92.22m | 683.46m | 92.00 | -- | 3.44 | -- | -- | -30.51 | -30.51 | 0.00 | 21.34 | 0.00 | -- | -- | 0.00 | -56.06 | -31.55 | -59.82 | -36.48 | -- | -- | -- | -365.87 | -- | -167.13 | 0.00 | -- | -- | -- | 0.5001 | -- | 78.21 | -- |
Holder | Shares | % Held |
---|---|---|
Commodore Capital LPas of 30 Jun 2024 | 7.15m | 8.78% |
Deep Track Capital LPas of 30 Jun 2024 | 6.10m | 7.50% |
BlackRock Fund Advisorsas of 30 Jun 2024 | 4.98m | 6.12% |
Driehaus Capital Management LLCas of 30 Jun 2024 | 2.54m | 3.12% |
Marshall Wace LLPas of 30 Jun 2024 | 2.16m | 2.66% |
Octagon Capital Advisors LPas of 30 Jun 2024 | 2.15m | 2.65% |
Blackstone Alternative Asset Management LPas of 30 Jun 2024 | 1.90m | 2.33% |
SSgA Funds Management, Inc.as of 30 Jun 2024 | 1.81m | 2.22% |
The Vanguard Group, Inc.as of 30 Jun 2024 | 1.55m | 1.91% |
Geode Capital Management LLCas of 30 Jun 2024 | 1.51m | 1.86% |